New cancer drug trial seeks to shrink tough tumors
NCT ID NCT07186842
Summary
This early-stage clinical trial is testing a new drug called BNT329 in people with advanced solid cancers that have a specific marker called CA19-9. The main goals are to find the safest and most effective dose and to see if the drug can shrink tumors or stop them from growing. The study will enroll about 245 participants whose cancers have not responded well to previous standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
-
Hospital Universitario HM Sanchinarro - START Madrid CIOCC
RECRUITINGMadrid, 28050, Spain
-
Hospital Universitario Quironsalud Madrid - NEXT Oncology
RECRUITINGPozuelo de Alarcón, 28223, Spain
-
The Royal Marsden Hospital
RECRUITINGSutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.